Aurinia Pharmaceuticals
Victoria, US · Founded 2009 · 3 known investors
Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs. The company's marketed product LUPKYNIS treats active lupus nephritis, and it is also developing aritinercept for broader autoimmune indications.
Founders & leadership
KV
Kurt von EmsterNamed on SEC filing
BR
Benjamin RovinskiNamed on SEC filing
CK
Chris KimNamed on SEC filing
DW
Donald WyattNamed on SEC filing
SW
Stephen W. ZarubyNamed on SEC filing
MM
Michael MartinNamed on SEC filing
DB
Dennis BourgeaultNamed on SEC filing
DP
Daniel ParkNamed on SEC filing
RM
Richard M. GlickmanNamed on SEC filing
PW
Peter WijngaardNamed on SEC filing
MT
Mr. TangChief Executive Officer and Chair of the Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$52M disclosed across 1 round · 2014
▶$52MraisedFeb 2014 · 22 investors · BiotechnologyRule 506(b)
▶$52MraisedFeb 2014 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kurt von EmsterDirector
- Benjamin RovinskiDirector
- Chris KimDirector
- Donald WyattDirector
- Stephen W. ZarubyExecutive Officer, Director
- Michael MartinExecutive Officer, Director
- Dennis BourgeaultExecutive Officer
- Daniel ParkDirector
- Richard M. GlickmanExecutive Officer, Director
- Peter WijngaardDirector
- Offering amount
- $52M
- Amount sold
- $52M
- Sales commissions
- $3.5M
- Placement agents
- Canaccord Genuity Inc., Leerink Partners LLC
- First sale
- Feb 2014
- Incorporated
- Corporation, Alberta, Canada, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Aurinia Pharmaceuticals do?
- Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs. The company's marketed product LUPKYNIS treats active lupus nephritis, and it is also developing aritinercept for broader autoimmune indications.
- Who are Aurinia Pharmaceuticals's investors?
- Aurinia Pharmaceuticals's investors include Lumira Ventures, New Enterprise Associates (NEA), venBio Partners.
- How much funding has Aurinia Pharmaceuticals raised?
- Aurinia Pharmaceuticals has disclosed $52M raised across 1 round.
- Where is Aurinia Pharmaceuticals headquartered?
- Aurinia Pharmaceuticals is headquartered in Victoria, US.